Group 1 contains mostly lymph node metastatic samples in which 69% (9/13) have deleted PTEN based on CN; Group 2 has mostly primary cancer samples in which 31% (11/35) have PTEN CN changes, whereas Group 3 consists of a majority of normal prostate cancer samples with only 4.7% (3/64) PTEN CN changes. The gene discussed is PTEN; the disease is prostate cancer.